Replies to post #237913 on Biotech Values

[DewDiligence]

ABBV 1Q21 Mavyret sales=$415M, -14% QoQ:

https://news.abbvie.com/news/press-releases/abbvie-reports-first-quarter-2021-financial-results.htm

The $415M consisted of: $170M US (-23% QoQ); and $245M ex-US (-6%, QoQ).

ABBV’s prior guidance for full-year 2021 Mavyret sales is $2.0B (#msg-161451655). This figure could still be met if patient starts (especially in the US) pick up due to lessening of COVID; however, ABBV may lower the guidance during today’s CC.

[DewDiligence]

1Q21 worldwide Botox sales=$1.01B, -1% QoQ*, +24% YoY:

https://news.abbvie.com/news/press-releases/abbvie-reports-first-quarter-2021-financial-results.htm

• US therapeutic: $429M (-9% QoQ*, +8% YoY)
• US cosmetic: $305M (+1 QoQ*, +43% YoY)
--
US total: $734M (58% therapeutic; 42% cosmetic) was 73% of worldwide total


• Ex-US therapeutic: $103M (+8% QoQ*, +15% YoY)
• Ex-US cosmetic: $172M (-9% QoQ*, +51% YoY)
--
Ex-US total: $275M (37% therapeutic; 63% cosmetic) was 27% of worldwide total


*Botox sales are seasonally stronger in the second and fourth calendar quarters than in the first and third quarters.

[dewophile]

My guess is covid depressed HCV sales from 20-30 percent